PERSONALIZED MEDICINE - CHEMIST’S POINT OF VIEW

Abstract

The paper discusses the basic principles of personalized medicine and, first of all, the problems of the design of «personalized» drugs.

Keywords

personalized medicine / drug design

References

[1] Ginsburg G.S., McCarthy J.J. Personalized medicine: Revolutionizing drug discovery and patient care // Trends in Biotechnology.- 2001.- Vol. 19 (12) - P. 491-496

[2] Пальцев М. Персонифицированная медицина // Наука в России.- 2011.- № 1.- C. 12-17.

[3] Zhang A., Sun H., Wang P., Han Y., Wang X. Future perspectives of personalized medicine intraditional Chinese medicine: A systems biology approach. // Complementary Therapies in Medicine.- 2012.- Vol. 20.- P. 93-99.

[4] Jain K.K. Personalized Medicine // Current Opin. Mol. Therap.- 2002.- Vol. 4 (6).- P. 548-558.

[5] Сычев Д.А., Антонов И.М., Загребин С.В. Алгоритмы дозирования варфарина, основанные на результатах фармакогенетического тестирования: реальная возможность оптимизации фармакотерапии // Рациональная фармакотерапия в кардиологии.- 2007.- Т. 3, № 2.- С. 59-66.

[6] Medawar P. The future of man // The Reith Lectures (BBC Radio 4, 1959).

[7] Pulendran B. Systems vaccinology: probing humanity’s diverse immune systems with vaccines // Proc. Natl. Acad. Sci. USA.- 2014.- Vol. 111.- P. 12300-12306.

[8] http://mkb-10.com/

[9] Баранов В.С., Баранова Е.В. Жить в гармониисо своими генами // Природа.- 2004.- № 12.- С. 3-9.

[10] Jergensen J.T. A challenging drug development process in the era of personalized medicine. // Drug Discovery Today.- 2011.- Vol. 16.- P. 891-897.

[11] Drews J. Strategic trends in the drug industry // Drug Discovery Today.- 2003.- Vol. 8 (9).- P. 411-420.

[12] Drews J., Ryser S. The role of innovation in drug development // Nat. Biotechnol.- 1997.- Vol.15.- P. 1318-1319.

[13] Pao W. A personal view on precision medicine.- 2016. Опубликовано онлайн: URL: www.roche.com (дата обращения 02.02.16).

[14] Marth J.D. A unified vision of the building blocks of life // Nature Cell Biology.- 2008.- Vol. 10 (9).- P. 1015-1016.

[15] Schork N.J. Time for one-person trials // Nature News.- 2015.- Vol. 520.- P. 609-611.

[16] Spear B.B., Heath-Chiozzi M., Huff J. Clinical application of pharmacogenetics // Trends Mol. Med.- 2001.- Vol. 7 (5).- P. 201-204.

[17] Freedman M.S. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β-therapy // Eur. J. Neurol.- 2014.- Vol. 21.- P. 377-387.

[18] Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment // N. Engl. J. Med.- 1988.- Vol. 318 (26).- P. 1728-1733.

[19] https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative.

[20] Toward precision medicine: building a new taxonomy of disease.- Washington, DC: National Academies Press, 2011.- 142 p.

[21] Ashley E.A. The precision medicine initiative: a new national effort // JAMA.- 2015.- Vol. 313 (21).- P. 2119-2120.

[22] Harries M., Smith I. The development and clinical use of trastuzumab (Herceptin) // Endocrine-Related Cancer.- 2002.- Vol. 9.- P. 7585.

[23] Tutt A., Robson M., Garber J.E. et. al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial // Lancet.- 2010.- Vol. 376 (9737).- P. 235-244.

[24] The case for personalized medicine.- 4th ed.- Personalized Medicine Coalition, 2014. Опубликовано онлайн: URL:http://www.personal-izedmedicinecoalition.org/Userfiles/PMCCorporate/file/pmc_the_case_for_personalized_medicine.pdf (дата обращения 02.02.16).

[25] Allison M. Is personalized medicine finally arriving? // Nat. Biotechnol.- 2008.- Vol. 26.- P. 509-517.

[26] Shin J., Kayser S.R., Langaee T.Y. Pharmacogenetics: from discovery to patient care // Am. J. Health Syst. Pharm.- 2009.- Vol. 66.- P. 625-637.

[27] Ikediobi O. N., Shin J., Nussbaum R. L. et al. UCSF Center for Translational and Policy Research on Personalized Medicine. Addressing the challenges of the clinical application of pharmacogenetic testing // Clin. Pharmacol. Ther.- 2009.- Vol. 86.- P. 28-31.

[28] Ginsburg G.S., McCarthy J.J. Personalized medicine: revolutionizing drug discovery and patient care // Trends Biotechnol.- 2001.- Vol. 19(12).- P. 491-496.

[29] Furka A., Sebestyen F., Asgedom M. et. al. General method for rapid synthesis of multicomponent peptide mixtures // Int. J. Peptide Protein Res.- 1991.- Vol. 37.- P. 487-493.

[30] Ahn B. C. Applications of molecular imaging in drug discovery and development process // Curr. Pharm. Biotechnol.- 2011.- Vol. 12 (4).- P. 459-468.

[31] Jorgensen J. T. Companion diagnostics: the key to personalized medicine // Expert Rev. Mol. Diagn.- 2015.- Vol. 15 (2).- P. 153-156.

[32] Ипатова О.М., Медведева Н.В., Арчаков А.И. и др. Трансляционная медицина - путь от фундаментальной биомедицинской науки в здравоохранение // Вестник РАМН.- 2012.- Т. 67, № 6.- С. 57-65.

[33] Jergensen J. T. Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development. // Expert Rev MolDiagn.- 2008.- Vol. 8 (6).- P. 689-695.

[34] Пиотровский Л. Б. Очерки о наномедицине.- СПб.: Росток, 2013.- 206 с.

[35] http://www.forbes.com/sites/henrymiller/2013/09/25/personalized-medicine-may-be-good-for-patients-but-bad-for-drug-companies-bot-tom-line/#68f6edc21d12

[36] Struewing J. P., Hartge P., Wacholder S. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews // N. Engl. J. Med.- 1997.- Vol. 336 (20).- P. 1401-1408.

[37] Hood L. A. Personal View of Molecular Technology and How It Has Changed Biology // J. Proteome Res.- 2002.- Vol. 1 (5).- P. 399409.

[38] Weston A. D., Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine // J. Proteome Res.- 2004.- Vol. 3.- P. 179-196.

[39] Sung N. S., Crowley W. F. Jr, Genel M. et. al. Central challenges facing the national clinical research enterprise // JAMA.- 2003.- Vol. 289 (10).- P. 1278-1287.

[40] Woolf S.H. The meaning of translational research and why it matters // JAMA.- 2008.- Vol. 299 (2).- P. 211-213.

[41] Аксенов В.А. Российская наномедицина: как выдать ситро за шампанское // Доказательная медицина и клиническая эпидемиология.- 2009.- № 2.- С. 38-42.

RIGHTS & PERMISSIONS

Piotrovskiy L.B.